Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite, which was an extended treat for some, was relaxing and invigorating, because that oh-so-familiar routine of meetings, conference calls, deadlines, and the like has predictably returned. You knew this would happen, though, yes? The world keeps spinning no matter how hard we may sometimes try to slow it down. So, to cope, we are brewing a cup of stimulation and invite you to join us. Meanwhile, here are some tidbits to get you started. Hope your day goes well and do keep in touch …

Novartis (NVS), which last week reported positive interim data for its experimental spinal muscular atrophy treatment, disclosed that an investigation is underway into whether a second clinical trial death could be related to the treatment, Reuters writes. The drug maker also reported that in addition to the death, a 6-month-old patient with type 1 SMA had recently died after undergoing treatment with the therapy, called Zolgensma, in a European trial. Food and Drug Administration approval is expected within weeks. The FDA submission was based on findings from a trial of 15 babies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!